– BELGIUM, Leuven – Oxurion NV (EBR: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical-stage portfolio in retinal vascular disorders, today announced the appointment of CFO Tom Graney to CEO role, taking over from Dr. Patrik De Haes who has decided to become Non-Executive Chairman.
His transatlantic experience in creating significant company and shareholder value makes him uniquely qualified to lead Oxurion as its next CEO as it moves its highly differentiated assets through clinical development.
“I am looking forward to supporting Tom and the rest of the Oxurion team in my new role as Chairman as we deliver a number of important clinical development milestones in the months ahead. I am confident that our drug candidates thathave the potential to make a significant difference to the lives of the large number of patients with sight threatening disease, who require better treatment options.” said Board Chairman, Dr. Patrik De Haes.
The outgoing Chairman, Thomas Clay, will remain on the Board as a Non-executive Director.
About Tom Graney
Tom Graney has extensive capital markets and business development experience in biotech as the CFO of several successful public companies. This includes having raised >$500M in capital for highly innovative companies like Oxurion and completing several value-creating business development transactions. Tom also has an impressive track record of developing high-performing teams and talent everywhere he has worked both in the United States and Europe.
Tom Graney joined Oxurion as CFO in October 2020 and has over 25 years of experience in senior finance, strategy, business development, and operational roles including most recently as CFO of Generation Bio (NASDAQ: GBIO), and before that CFO of Vertex Pharmaceuticals (NASDAQ: VRTX), and CFO and Head of Corporate Strategy at Ironwood Pharmaceuticals (NASDAQ: IRWD). Earlier in his career, he spent 20 years with Johnson and Johnson, including CFO roles at Ethicon, Tibotec, and Janssen.
Tom also serves on the board of AC Immune (NASDAQ: ACIU).
Tom has an MBA in finance, marketing, and international business from the Leonard N. Stern School of Business at New York University and a BS in accounting from the University of Delaware. He is also a CFA charterholder.
Tom Graney said, “I am very excited and honored to become the CEO of Oxurion as we build out our plan to create an important ophthalmic company grounded in exceptional science. I am confident that with THR-149 and THR-687, two highly promising and differentiated new drug candidates, coupled with our extremely talented team, Oxurion has the potential to successfully address a broad range of retinal vascular disorders. This would allow us to generate significant value for patients, payors, and shareholders as we look to disrupt and grow the $12 billion market for retinal vascular disorders.”
About Oxurion
Oxurion is a biopharmaceutical company developing a next-generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Oxurion is aiming to build the leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for the 40% of DME patients who respond suboptimally to anti-VEGF therapy. THR-149 has shown positive topline Phase 1 results for the treatment of DME. The company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 in DME patients who previously responded suboptimally to anti-VEGF therapy.
- THR-687 is a pan-RGD integrin antagonist that is initially being developed as a potential first-line therapy for DME patients. Positive topline results in Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020. THR-687 is expected to enter a Phase 2 clinical trial in mid-2021. THR-687 also has the potential to deliver improved treatment outcomes for patients with wet AMD and RVO.
Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
For more information, visit www.oxurion.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.